Cargando…

Technical feasibility of [(18)F]FET and [(18)F]FAZA PET guided radiotherapy in a F98 glioblastoma rat model

BACKGROUND: Glioblastoma (GB) is the most common primary malignant brain tumor. Standard medical treatment consists of a maximal safe surgical resection, subsequently radiation therapy (RT) and chemotherapy with temozolomide (TMZ). An accurate definition of the tumor volume is of utmost importance f...

Descripción completa

Detalles Bibliográficos
Autores principales: Verhoeven, Jeroen, Bolcaen, Julie, De Meulenaere, Valerie, Kersemans, Ken, Descamps, Benedicte, Donche, Sam, Van den Broecke, Caroline, Boterberg, Tom, Kalala, Jean-Pierre, Deblaere, Karel, Vanhove, Christian, De Vos, Filip, Goethals, Ingeborg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543630/
https://www.ncbi.nlm.nih.gov/pubmed/31146757
http://dx.doi.org/10.1186/s13014-019-1290-4
_version_ 1783423116979994624
author Verhoeven, Jeroen
Bolcaen, Julie
De Meulenaere, Valerie
Kersemans, Ken
Descamps, Benedicte
Donche, Sam
Van den Broecke, Caroline
Boterberg, Tom
Kalala, Jean-Pierre
Deblaere, Karel
Vanhove, Christian
De Vos, Filip
Goethals, Ingeborg
author_facet Verhoeven, Jeroen
Bolcaen, Julie
De Meulenaere, Valerie
Kersemans, Ken
Descamps, Benedicte
Donche, Sam
Van den Broecke, Caroline
Boterberg, Tom
Kalala, Jean-Pierre
Deblaere, Karel
Vanhove, Christian
De Vos, Filip
Goethals, Ingeborg
author_sort Verhoeven, Jeroen
collection PubMed
description BACKGROUND: Glioblastoma (GB) is the most common primary malignant brain tumor. Standard medical treatment consists of a maximal safe surgical resection, subsequently radiation therapy (RT) and chemotherapy with temozolomide (TMZ). An accurate definition of the tumor volume is of utmost importance for guiding RT. In this project we investigated the feasibility and treatment response of subvolume boosting to a PET-defined tumor part. METHOD: F98 GB cells inoculated in the rat brain were imaged using T2- and contrast-enhanced T1-weighted (T1w) MRI. A dose of 20 Gy (5 × 5 mm(2)) was delivered to the target volume delineated based on T1w MRI for three treatment groups. Two of those treatment groups received an additional radiation boost of 5 Gy (1 × 1 mm(2)) delivered to the region either with maximum [(18)F]FET or [(18)F]FAZA PET tracer uptake, respectively. All therapy groups received intraperitoneal (IP) injections of TMZ. Finally, a control group received no RT and only control IP injections. The average, minimum and maximum dose, as well as the D(90)-, D(50)- and D(2)- values were calculated for nine rats using both RT plans. To evaluate response to therapy, follow-up tumor volumes were delineated based on T1w MRI. RESULTS: When comparing the dose volume histograms, a significant difference was found exclusively between the D(2)-values. A significant difference in tumor growth was only found between active therapy and sham therapy respectively, while no significant differences were found when comparing the three treatment groups. CONCLUSION: In this study we showed the feasibility of PET guided subvolume boosting of F98 glioblastoma in rats. No evidence was found for a beneficial effect regarding tumor response. However, improvements for dose targeting in rodents and studies investigating new targeted drugs for GB treatment are mandatory. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13014-019-1290-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6543630
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65436302019-06-04 Technical feasibility of [(18)F]FET and [(18)F]FAZA PET guided radiotherapy in a F98 glioblastoma rat model Verhoeven, Jeroen Bolcaen, Julie De Meulenaere, Valerie Kersemans, Ken Descamps, Benedicte Donche, Sam Van den Broecke, Caroline Boterberg, Tom Kalala, Jean-Pierre Deblaere, Karel Vanhove, Christian De Vos, Filip Goethals, Ingeborg Radiat Oncol Research BACKGROUND: Glioblastoma (GB) is the most common primary malignant brain tumor. Standard medical treatment consists of a maximal safe surgical resection, subsequently radiation therapy (RT) and chemotherapy with temozolomide (TMZ). An accurate definition of the tumor volume is of utmost importance for guiding RT. In this project we investigated the feasibility and treatment response of subvolume boosting to a PET-defined tumor part. METHOD: F98 GB cells inoculated in the rat brain were imaged using T2- and contrast-enhanced T1-weighted (T1w) MRI. A dose of 20 Gy (5 × 5 mm(2)) was delivered to the target volume delineated based on T1w MRI for three treatment groups. Two of those treatment groups received an additional radiation boost of 5 Gy (1 × 1 mm(2)) delivered to the region either with maximum [(18)F]FET or [(18)F]FAZA PET tracer uptake, respectively. All therapy groups received intraperitoneal (IP) injections of TMZ. Finally, a control group received no RT and only control IP injections. The average, minimum and maximum dose, as well as the D(90)-, D(50)- and D(2)- values were calculated for nine rats using both RT plans. To evaluate response to therapy, follow-up tumor volumes were delineated based on T1w MRI. RESULTS: When comparing the dose volume histograms, a significant difference was found exclusively between the D(2)-values. A significant difference in tumor growth was only found between active therapy and sham therapy respectively, while no significant differences were found when comparing the three treatment groups. CONCLUSION: In this study we showed the feasibility of PET guided subvolume boosting of F98 glioblastoma in rats. No evidence was found for a beneficial effect regarding tumor response. However, improvements for dose targeting in rodents and studies investigating new targeted drugs for GB treatment are mandatory. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13014-019-1290-4) contains supplementary material, which is available to authorized users. BioMed Central 2019-05-30 /pmc/articles/PMC6543630/ /pubmed/31146757 http://dx.doi.org/10.1186/s13014-019-1290-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Verhoeven, Jeroen
Bolcaen, Julie
De Meulenaere, Valerie
Kersemans, Ken
Descamps, Benedicte
Donche, Sam
Van den Broecke, Caroline
Boterberg, Tom
Kalala, Jean-Pierre
Deblaere, Karel
Vanhove, Christian
De Vos, Filip
Goethals, Ingeborg
Technical feasibility of [(18)F]FET and [(18)F]FAZA PET guided radiotherapy in a F98 glioblastoma rat model
title Technical feasibility of [(18)F]FET and [(18)F]FAZA PET guided radiotherapy in a F98 glioblastoma rat model
title_full Technical feasibility of [(18)F]FET and [(18)F]FAZA PET guided radiotherapy in a F98 glioblastoma rat model
title_fullStr Technical feasibility of [(18)F]FET and [(18)F]FAZA PET guided radiotherapy in a F98 glioblastoma rat model
title_full_unstemmed Technical feasibility of [(18)F]FET and [(18)F]FAZA PET guided radiotherapy in a F98 glioblastoma rat model
title_short Technical feasibility of [(18)F]FET and [(18)F]FAZA PET guided radiotherapy in a F98 glioblastoma rat model
title_sort technical feasibility of [(18)f]fet and [(18)f]faza pet guided radiotherapy in a f98 glioblastoma rat model
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543630/
https://www.ncbi.nlm.nih.gov/pubmed/31146757
http://dx.doi.org/10.1186/s13014-019-1290-4
work_keys_str_mv AT verhoevenjeroen technicalfeasibilityof18ffetand18ffazapetguidedradiotherapyinaf98glioblastomaratmodel
AT bolcaenjulie technicalfeasibilityof18ffetand18ffazapetguidedradiotherapyinaf98glioblastomaratmodel
AT demeulenaerevalerie technicalfeasibilityof18ffetand18ffazapetguidedradiotherapyinaf98glioblastomaratmodel
AT kersemansken technicalfeasibilityof18ffetand18ffazapetguidedradiotherapyinaf98glioblastomaratmodel
AT descampsbenedicte technicalfeasibilityof18ffetand18ffazapetguidedradiotherapyinaf98glioblastomaratmodel
AT donchesam technicalfeasibilityof18ffetand18ffazapetguidedradiotherapyinaf98glioblastomaratmodel
AT vandenbroeckecaroline technicalfeasibilityof18ffetand18ffazapetguidedradiotherapyinaf98glioblastomaratmodel
AT boterbergtom technicalfeasibilityof18ffetand18ffazapetguidedradiotherapyinaf98glioblastomaratmodel
AT kalalajeanpierre technicalfeasibilityof18ffetand18ffazapetguidedradiotherapyinaf98glioblastomaratmodel
AT deblaerekarel technicalfeasibilityof18ffetand18ffazapetguidedradiotherapyinaf98glioblastomaratmodel
AT vanhovechristian technicalfeasibilityof18ffetand18ffazapetguidedradiotherapyinaf98glioblastomaratmodel
AT devosfilip technicalfeasibilityof18ffetand18ffazapetguidedradiotherapyinaf98glioblastomaratmodel
AT goethalsingeborg technicalfeasibilityof18ffetand18ffazapetguidedradiotherapyinaf98glioblastomaratmodel